---
title: Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
date: '2024-06-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38828984/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240603181443&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Among patients with resectable, macroscopic stage III melanoma,
  neoadjuvant ipilimumab plus nivolumab followed by surgery and response-driven adjuvant
  therapy resulted in longer event-free survival than surgery followed by adjuvant
  nivolumab. (Funded by Bristol Myers Squibb and others; NADINA ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: Among patients with resectable, macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab followed by surgery and response-driven adjuvant therapy resulted in longer event-free survival than surgery followed by adjuvant nivolumab. (Funded by Bristol Myers Squibb and others; NADINA ClinicalTrials.gov number, ...